www.ukhd.de
Notfall
Blutspende
International
Patients
www.pflege-ukhd.de
SCIENCE TALK
With our format "SCIENCE TALK - the after-hours conversation over mineral water and crispy knowledge snacks", we are launching a test balloon to transfer the relaxed exchange of information - learning-by-doing training through interaction - between colleagues and specialist areas at the patient's bedside or in the corridor to a digital level.
We look forward to your feedback, suggestions, (constructive) criticism or questions at: martin.zeier@med.uni-heidelberg.de
SCIENCE TALK
THE SPECIALIST TALKabout anticoagulation
Cardiologist Prof. Evangelos Giannitsis and nephrologist Prof. Martin Zeier discuss atrial fibrillation in patients with chronic kidney disease and dialysis patients, as well as how anticoagulation should be administered in these patients: +49 6221 568080
On the set in alphabetical order:
Evangelos Giannitsis - Chest Pain Unit | Cardiology University Hospital, Heidelberg
Martin Zeier - Nephrology | Renal Center at the University Hospital, Heidelberg
SCIENCE TALK
THE SPECIALIST'S TALKabout hereditary kidney diseases
In this program, the human geneticist and the nephrologist discuss the topic of nephrogenetics and the most important kidney diseases that affect nephrogenetics. Consultation on Wednesday mornings by appointment at: +49 6221 565087
On the set in alphabetical order:
Matias Simons - Nephrogenetics | Institute of Human Genetics University Hospital, Heidelberg
Martin Zeier - Nephrology | Renal Center at the University Hospital, Heidelberg
SCIENCE TALK
THE SPECIALIST TALKabout the treatment of hyperkaliaemia
In this program, the cardiologist and the nephrologist discuss challenges in the treatment of hyperkaliaemia against a polypharmaceutical background.
On set in alphabetical order:
Evangelos Giannitsis - Cardiology | Internal Medicine III, University Hospital, Heidelberg
Martin Zeier - Nephrology | Renal Center at the University Hospital, Heidelberg
SCIENCE TALK
THE SPECIALIST'S TALKabout the use of SGLT2 inhibitors
In this program, the cardiologist and nephrologist present treatment options for heart and kidney failure using glyphocyne therapy.
On set in alphabetical order:
Evangelos Giannitsis - Cardiology | Internal Medicine III, University Hospital, Heidelberg
Martin Zeier - Nephrology | Renal Center at the University Hospital, Heidelberg
Glyphlocyne therapy using SGLT2 inhibitors has already proven its advantages in the treatment of diabetes, as the mortality rate among patients has been significantly reduced in exchange for the already relatively low side effects.
For Prof. Giannitsis, this alone makes this drug worth recommending. However, success has now also been shown in the treatment of patients with heart failure and renal insufficiency.
The glyphlocyne substance class is particularly interesting for research at the Kidney Center because drugs from this class have been able to delay the progression of renal insufficiency and have also been shown to have a beneficial effect on heart disease. The treatment therefore targets the systemic disease.
The clinicians Zeier and Giannitsis present the treatment principle in a video.